Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaprazan glurate effect on amoxicillin PK in healthy participants
NCT07308041Phase 1Completed
- Sponsor
- Cinclus Pharma
- Start
- Nov 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linaprazan glurate in gastroesophageal reflux disease (GERD), sponsored by Cinclus Pharma. Primary endpoints: Area Under the Concentration-Time Curve of amoxicillin at Day 8, Maximum Plasma Concentration of amoxicillin at Day 8 and 2 more. Started Nov 2025; status: completed.
02
Drugs
linaprazan glurate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07308041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308041.